We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App





Horiba Showcases Latest Hematology and Hemostasis Solutions at EUROMEDLAB 2022

By LabMedica International staff writers
Posted on 11 Apr 2022

Horiba Medical (Kyoto, Japan) showcased its hematology and hemostasis solutions at the EUROMEDLAB 2022 which took place from April 10 to 14 at the ICM Internationales Congress Center, Munich, Germany. More...

The company also presented scientific posters on its high range hematology solutions during the poster session time.

At its exhibition booth, Horiba showcased its automation high-end HELO Global Hematology Solution covering all the needs of a high throughput automated hematology platform. Thanks to its data, tube management, waste, blood film and digitalization management capability, HELO not only addresses all the needs of laboratories, but helps to optimize their TAT, floor space and reagent storage. Among its Yumizen range of hematology solutions, Horiba displayed its Yumizen H2500/H1500 and the Yumizen H550 hematology analyzers. The Yumizen H2500/H1500 has a real throughput of 120 samples per hour for CBC-DIFF NRBC and slides and come with on board reagents (5 for Yumizen H2500 and 4 for Yumizen H1500). Along with testing for up to 55 parameters, their automatic 360°C rotative sample mixing provides perfect homogeneity. On the other hand, the Yumizen H550 is a compact 6-diff hematology analyzer with an auto sampling system which aims at providing a full walk away capability to a variety of clinical environments: hospitals, satellite labs, emergency care, small independent labs, and doctors’ offices.

Among its Yumizen range of hemostasis solutions, Horiba displayed its Yumizen G1550/G1500 and Yumizen G400 hemostasis analyzers. The Yumizen G1550/G1500 automated analyzer offers routine and specialized testing in a single analysis system along with liquid and ready-to-use reagents for 80% of laboratory activity. It offers up to eight measuring channels with two wavelength combinations, continuous loading, and simplified anteriority management thanks to a large database of 1,000,000 results. The Yumizen G400 semi-automated hemostasis analyzer offers four independent measuring channels and 20 incubation positions and is easy to operate with an innovative user interface. Other solutions on display at the Horiba EUROMEDLAB 2022 exhibition booth included the Yumizen SPS slide maker, the CellaVision DC-1 digital cell morphology system, the Yumizen P8000 middleware and expert validation station and the Yumizen T6000 automated conveyor.

Related Links:
Horiba Medical 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Varicella Zoster Virus Assay
LIAISON VZV Assay Panel (IgG HT, IgM)
New
PBC Assay
Primary Biliary Cholangitis Assays
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.